Top Articles

History Machado-Joseph disease (MJD) is an autosomal dominant (AD) spinocerebellar ataxia (SCA) initially described in descendants of immigrants from the Portuguese islands of the Azores. It was in 1972 that Kenneth K. Nakano and colleagues described the Machado family, with an AD, late onset, cerebellar ataxia with peripheral neuropathy. All family members were descendants from Guilherme Machado, who had migrated from São Miguel (Azores) to Massachusetts in the late nineteenth or early twentieth centuries.

Slovakia, officially the Slovak Republic, is a country in Central Europe. The total area of the Slovak territory is 49 036 km2 and is mostly mountainous. The population is over 5 million. The capital and largest city is Bratislava. However, the Slovak Republic is a young state (established on January 1st, 1993, by the split of Czechoslovakia), indeed it is an old country with rich historical heritage.

THE EUROPEAN ACADEMY OF NEUROLOGY PRESENTS ‘CHALLENGING THE GLOBAL BURDEN OF BRAIN DISEASE’, A COLLABORATION WITH ITN PRODUCTIONS In a unique communications partnership, European Academy of Neurology (EAN) and ITN Productions are producing a news and current affairs-style programme highlighting… Continue Reading

This Brain Awareness Week EFNA are launching a Survey of Young Europeans with Neurological Conditions.

On 12-14 April the Dystonia Europe 25th Anniversary Conference and D-DAYs 2018 will take place in Brussels, Belgium. The 3-day event will include a special lunch in the EU Parliament.

You can follow the announcement at: www.thebrainprize.org Four neuroscientists working in the UK, Belgium and Germany have today (6 March) won the world’s most valuable prize for brain research.   The 2018 Brain Prize is awarded to Bart De Strooper (London… Continue Reading

Eveline Sipido: Thank you for hosting applicants of the EAN Clinical Fellowship. How would you evaluate this EAN educational opportunity? Mark Edwards (ME)/Anthony Pereira (AP): St George’s runs one of the largest Neurology & Stroke training schemes in the UK.  We cover the UK curriculum on site and so can provide a comprehensive clinical training in neurology and stroke medicine.

The next Exam of the European Board of Neurology (EBN) will take place on Friday June 15th at the EAN congress site in Lisbon. Since Prof. Wolfgang Grisold from Vienna successfully started this yearly event in 2009 we are now… Continue Reading

This year, the “History of Neuroscience Visit” will be at the Egas Moniz Museum: (€30 fee/€ 20 reduced fee) The participants of the History of Neuroscience Visit will be picked up by bus at 13.00h on Monday, June 18. All… Continue Reading

Antonio Federico (AF): Dear Professor, you founded Orphanet and gave a great contribution on the development of information about Rare Diseases in Europe. Can you summarize your past activities and the difficulties you had? Segolene Aymé (SA): That is a long story as I started to build a database of genetic diseases and of malformation syndromes described in the literature, in the mid-seventies, when I started as a clinician in medical genetics, lost in diagnosing most of the patients attending our clinic in Marseilles.

Elena Moro: Dear Prof. Vincent, you have recently been awarded with the WFN Medal for Scientific Achievement in Neurology. We congratulate with you for this well-deserved outstanding recognition! In light of your longstanding experience in the world of neuro-immunology in particular, what do you think is it the most recent important discovery in your field? Angela Vincent (AV): Well first of all thank you for the congratulations.  I am thrilled to receive the WFN Medal and it is much appreciated. Neuroimmunology is a relatively recent discipline – probably only first defined in the 1980s. 

As in the previous years, EANpages asked EAN committee members, panel chairs, and invited speakers  which session one should not miss at the upcoming congress in Lisbon 2018. Please find their answers below!

Antonio Federico (AF): On January 29-30, there has been in Tubingen the Kick-Off Meeting of the EU Project Solve-RD. You and Prof. Olaf Riess are coordinating this project. Can you summarize the aim and the activities of this important project? Holm Graessner (HG): To obtain a molecularly confirmed diagnosis remains one of the largest challenges for rare disease patients. To jointly tackle this challenge a core group of four European Reference Networks including the European Reference Network for Rare Neurological Diseases has motivated, designed and put together the Solve-RD project which is the first ERN based H2020 funded research project. Solve-RD brings together 21 partners from 10 countries which will be running from 2018 to 2022.